

## Drug Utilization Review Board Meeting

**June 6, 2013**

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
<b>New Drug Reviews</b>			
<b>Multiple Sclerosis Agent</b>			
	Aubagio (Oral) Tablet	NP/PA	NP/PA
<b>Antineoplastic</b>			
	Bosulif (Oral) Tablet	P/PA	P/PA
<b>Irritable Bowel Syndrome - Constipation</b>			
	Linzess (Oral) Tablet	NP/PA	NP/PA
<b>Antispasmodic</b>			
	Myrbetriq (Oral) Tablet Extended-Release	NP/PA	NP/PA
<b>Antineoplastic</b>			
	Stivarga (Oral) Tablet	P/PA	P/PA
<b>Antineoplastic</b>			
	Synribo (Subcutaneous) Vial	P/PA	P/PA
<b>Chronic Obstructive Pulmonary Disorder Inhaler</b>			
	Tudorza (Inhalation)	NP/PA	NP/PA
<b>Biologic Immunomodulator</b>			
	Xeljanz (Oral) Tablet	NP/PA	NP/PA
<b>Class Reviews</b>			
The following classes were reviewed with a recommendation for change in PDL status.			
<b>Anaphylaxis Therapy</b>			
	Auvi-Q (Injection)	NP	NP/PA
<b>Angiotensin Converting Enzyme Inhibitors and Combinations</b>			
	Amlodipine-Benazepril (Oral) Capsule	NP/PA	P
	Lotrel (Oral) Capsule	P	NP/PA

Antidepressants – Selective Serotonin Reuptake Inhibitors			
	Escitalopram Oxalate (Oral) Solution	NP/PA	P
	Lexapro (Oral) Solution	P	NP/PA
Antifungals - Oral			
	Griseofulvin (Oral) Microsized Tablet	P	NP/PA
Antispasmodics			
	Tropium Chloride (Oral) Tablet	P	NP/PA
Atypical Antipsychotics – Long-Acting Injectables			
	Abilify Maintena (Intramuscular) Vial	NP/PA	NP/PA
Betalactam-Clavulanate Combinations			
	Amoxicillin Trihydrate-Potassium Clavulanate (Oral) Tablet 250mg-125mg	P	NP/PA
	Augmentin (Oral) Suspension for Reconstitution 250mg-62.5mg/5ml	P	NP/PA
Calcium Channel Blockers			
	Isradipine (Oral) Capsule	P	NP/PA
	Nicardipine Hydrochloride (Oral) Capsule	P	NP/PA
	Verapamil Extended-Release PM (Oral) Capsule 24 Hour	P	NP/PA
Chronic Obstructive Pulmonary Disorder Inhalers			
	Combivent Respimat (Inhalation)	NP/PA	P
Contraceptives - Emergency			
	Next Choice One Dose (Oral) Tablet	NP/PA	P
Diabetic – Oral			
	Chlorpropamide (Oral) Tablet	P	NP/PA
	Fortamet (Oral) Tab Extended-Release	P	NP/PA
	Starlix (Oral) Tablet	NP/PA	P

	Tolazamide (Oral) Tablet	P	NP/PA
	Tolbutamide (Oral) Tablet	P	NP/PA
Gastrointestinal – Antiulcer Antiinfectives			
	Prevpac (Oral) Combination Package	NP/PA	P/PA
	Pylera (Oral) Capsule	NP/PA	P/PA
Gastrointestinal – Digestive Enzymes			
	Pancreaze (Oral) Capsule Delayed-Release	P	NP/PA with grandfathering
Herpes Agents - Oral			
	Valacyclovir (Oral) Tablet	NP/PA	P
	Valtrex (Oral) Tablet	P	NP
Ophthalmic - Miscellaneous			
	Neomycin-Polymixin B-Hydrocortisone (Ophthalmic) Drops Suspension	P	NP/PA
Prenatal Vitamins			
	Citranatal DHA Products	NP/PA	P
	DHA Products that cost more than \$26 per claim	P and NP/PA	NP/PA
Topical Antipsoriatics			
	Calcipotriene (Topical) Solution	NP/PA	P
	Dovonex (Topical) Solution	P	NP/PA
Topical - Antivirals			
	Denavir (Topical) Cream	P	NP/PA
Topical – Genital Warts			
	Veregen (Topical) Ointment	P	NP/PA
Urinary Antiinfectives			
	Urelle (Oral) Tablet	P	NP/PA

The recommendations on the following classes reviewed remained the same as the current PDL status, which is located at [http://dch.georgia.gov/00/channel\\_title/0,2094,31446711\\_32050640,00.html](http://dch.georgia.gov/00/channel_title/0,2094,31446711_32050640,00.html).

Beta Adrenergics – Short-Acting Nebulizers	No Change – Leave as is
Contraceptives – Biphasic - Oral	No Change – Leave as is
Contraceptives – Progestins - Oral	No Change – Leave as is
Contraceptives – Triphasic - Oral	No Change – Leave as is
Cough and Cold Products	No Change – Leave as is
Drugs for Gout	No Change – Leave as is
Fluoroquinolones - Oral	No Change – Leave as is
Glucocorticoids - Oral	No Change – Leave as is
Hemostatics	No Change – Leave as is
Immunosuppressants	No Change – Leave as is
Leukotriene Modifiers	No Change – Leave as is
Sedative Hypnotics	No Change – Leave as is
Statins	No Change – Leave as is
Topical - Enzymes	No Change – Leave as is
Topical - Local Anesthetics	No Change – Leave as is

PDL = Preferred Drug List; P = Preferred; NP = Non-Preferred; PA = Prior Authorization